The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
Open accessAbstract
Purpose: The main purpose of this study was to determine the prevalence of pathogenic BRCA1 and BRCA2 mutations in a consecutively ascertained clinic-based cohort of patients with pancreatic ductal adenocarcinoma and describe the clinical and family history characteristics. Patients and Methods: Unselected, consecutive, incident patients with pancreatic ductal adenocarcinoma were recruited at a single cancer center over a 2-year period. Participants provided blood for DNA analysis and cancer family history, and cancer treatment records were reviewed. DNA from all patients was analyzed by Sanger sequencing and multiplex ligation-dependent probe amplification for germline variants in BRCA1 and BRCA2. Results: Three hundred six patients were eligible for analysis. Pathogenic germline BRCA mutations were identified in 14 patients (4.6%; 95% CI, 2.2% to 6.9%), including 11 patients with a BRCA2 mutation and three patients with a BRCA1 mutation. Having a cancer family history that met genetic testing criteria of the National Comprehensive Cancer Network or the Ontario Ministry of Health and Long-Term Care or self-reporting as Ashkenazi Jewish was significantly associated with BRCA mutation carrier status (P = .02, P < .001, and P = .05, respectively). However, the majority of the BRCA mutation–positive patients did not actually meet these genetic testing criteria. Conclusion: Pathogenic BRCA mutations were identified in 4.6% of a large cohort of clinic-based patients. Considering the implications for family members of BRCA carriers, and possibly tailored chemotherapeutic treatment of patients, our finding has implications for broader BRCA genetic testing for patients with pancreatic ductal adenocarcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent studies estimate that genomic risk contributes to up to 8% of PDAC cases,180–184”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [184]
In the citing paper
“However, these classic features have poor sensitivity in identifying individuals at high genomic risk for pancreatic cancer.182–185”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [184]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.
Easton, D. F., Ford, D., & Bishop, D. T. (1995) · PubMed Central · Cited by 1,602
Cancer risks in BRCA2 mutation carriers.
Olsson, H. (1999) · Journal of the National Cancer Institute · doi:10.1093/jnci/91.15.1310 · Cited by 1,404
Cancer Incidence in BRCA1 mutation carriers.
Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,075
Ashworth, A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.0812 · Cited by 872
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826
Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784
Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B. P., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj465 · Cited by 678
Self-citationGermline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.
Goggins, M., Schutte, M. E. M., Lü, J., Moskaluk, C. A., Weinstein, C. L., Petersen, G. M., Yeo, C. J., Jackson, C. E., Lynch, H. T., Hruban, R. H., et al. (1996) · PubMed · Cited by 642
Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L. A., Whittemore, A. S., McGuire, V. M., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6607 · Cited by 495
ATM Mutations in Patients with Hereditary Pancreatic Cancer
Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491
Self-citationBRCA2 germline mutations in familial pancreatic carcinoma
Hahn, S. A., Greenhalf, B., Ellis, I., Sina-Frey, M., Rieder, H., Korte, B., Gerdes, B., Kress, R., Ziegler, A., Raeburn, J. A., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.3.214 · Cited by 480
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
Golan, T., Kanji, Z. S., Epelbaum, R., Devaud, N., Dagan, E., Holter, S., Aderka, D., Paluch–Shimon, S., Kaufman, B., Gershoni‐Baruch, R., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.418 · Cited by 442
Self-citationMurphy, K. M., Brune, K. A., Griffin, C. A., Sollenberger, J. E., Petersen, G. M., Bansal, R. K., Hruban, R. H., & Kern, S. E. (2002) · PubMed · Cited by 435
LaDuca, H., Stuenkel, A. J., Dolinsky, J. S., Keiles, S. B., Tandy, S., Pesaran, T. F., Chen, E. Y., Gau, C., Palmaer, E., Shoaepour, K., et al. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.40 · Cited by 334
Win, A. K., Young, J., Lindor, N., Tucker, K., Ahnen, D., Young, G., Buchanan, D., Clendenning, M., Giles, G., Winship, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5590 · Cited by 324
Self-citationLevy‐Lahad, E., Catane, R., Eisenberg, S., Kaufman, B., Hornreich, G., Lishinsky, E., Shohat, M., Weber, B., Beller, U., Lahad, A., et al. (1997) · Europe PMC (PubMed Central) · Cited by 316
Tersmette, A. C., Petersen, G. M., Offerhaus, G. J. A., Falatko, F. C., Brune, K. A., Goggins, M., Rozenblum, E., Wilentz, R. E., Yeo, C. J., Cameron, J. L., et al. (2001) · PubMed · Cited by 307
The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer
Couch, F. J., Johnson, M. R., Rabe, K. G., Brune, K. A., de Andrade, M., Goggins, M., Rothenmund, H., Gallinger, S., Klein, A. P., Petersen, G. M., et al. (2007) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0783 · Cited by 273
Self-citationThe incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
T. H. B. C. S. G., Iqbal, J., Ragone, A., Lubinski, J., Lynch, H. T., Moller, P., Ghadirian, P., Foulkes, W. D., Armel, S., Eisen, A., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.483 · Cited by 252
Self-citationLowery, M. A., Kelsen, D. P., Stadler, Z. K., Yu, K. H., Janjigian, Y. Y., Ludwig, E., D’Adamo, D. R., Salo‐Mullen, E. E., Robson, M. E., Allen, P. J., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0185 · Cited by 248
Multiplex Genetic Testing for Cancer Susceptibility: Out on the High Wire Without a Net?
Domchek, S. M., Bradbury, A. R., Garber, J. E., Offit, K., & Robson, M. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.9403 · Cited by 237
Lal, G., Liu, G., Schmocker, B., Kaurah, P., Özçelik, H., Narod, S. A., Redston, M. S., & Gallinger, S. (2000) · PubMed · Cited by 233
Self-citationGermline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients
Özcelik, H., Schmocker, B., Nicola, N. D., Shi, X.-H., Langer, B., Moore, M. J., Taylor, B., Narod, S. A., Darlington, G., Andrulis, I. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-17 · Cited by 225
Self-citationBRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W. R., Brennan, M. F., Offit, K., & Robson, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5546 · Cited by 206
Tutt, A. N. J., Lord, C. J., McCabe, N., Farmer, H., Turner, N. C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 198
Tischkowitz, M. D., Sabbaghian, N., Hamel, N., Borgida, A., Rosner, C., Taherian, N., Srivastava, A., Holter, S., Rothenmund, H., Ghadirian, P., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.055 · Cited by 187
Self-citationResta, N., Pierannunzio, D., Lenato, G. M., Stella, A., Capocaccia, R., Bagnulo, R., Lastella, P., Susca, F. C., Bozzao, C., Loconte, D. C., et al. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2012.12.018 · Cited by 157
Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience
Al-Sukhni, W., Borgida, A., Rothenmund, H., Holter, S., Semotiuk, K., Grant, R. C., Wilson, S. R., Moore, M. J., Narod, S. A., Jhaveri, K. S., et al. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1781-6 · Cited by 150
Self-citationPrevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling
McWilliams, R. R., Wieben, E. D., Rabe, K. G., Pedersen, K. S., Wu, Y., Sicotte, H., & Petersen, G. M. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.198 · Cited by 135
Genomic rearrangements in BRCA1 and BRCA2: a literature review
Ewald, I. P., Ribeiro, P. L. I., Palmero, E. I., Cossio, S. L., Giugliani, R., & Ashton‐Prolla, P. (2009) · Genetics and Molecular Biology · doi:10.1590/s1415-47572009005000049 · Cited by 101
Lucas, A. L., Shakya, R., Lipsyc, M. D., Mitchel, E. B., Kumar, S., Hwang, C., Deng, L., DeVoe, C., Chabot, J. A., Szabolcs, M. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3020 · Cited by 69
Sonnenblick, A., Kadouri, L., Appelbaum, L., Peretz, T., Sagi, M., Goldberg, Y., & Hubert, A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.12.3.16292 · Cited by 63
Harinck, F., Kluijt, I., van Mil, S. E., Waisfisz, Q., van Os, T. A. M., Aalfs, C. M., Wagner, A., Olderode-Berends, M. J. W., Sijmons, R. H., Kuipers, E. J., et al. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.226 · Cited by 42
Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome
Gargiulo, S., Torrini, M., Ollila, S., Nasti, S., Pastorino, L., Cusano, R., Bonelli, L. A., Battistuzzi, L., Mastracci, L., Bruno, W., et al. (2009) · Familial Cancer · doi:10.1007/s10689-009-9285-1 · Cited by 40
(2013) · Gut · doi:10.1136/gutjnl-2012-303108corr1 · Cited by 25
Borgida, A. (2011) · Canadian Journal of Surgery · doi:10.1503/cjs.026409 · Cited by 22
Self-citationLaitman, Y., Herskovitz, L., Golan, T., Kaufman, B., Paluch, S. S., & Friedman, E. (2012) · Familial Cancer · doi:10.1007/s10689-011-9507-1 · Cited by 11
Flagged first, then by citations
Research works printed but not linked: 5
- Lal G, 2000, Cancer Res, 60, 409
- Tersmette AC, 2001, Clin Cancer Res, 7, 738
- Murphy KM, 2002, Cancer Res, 62, 3789
- Goggins M, 1996, Cancer Res, 56, 5360
- Levy-Lahad E, 1997, Am J Hum Genet, 60, 1059
Cited by
Sorted by citations
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M. M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V. M., Czito, B. G., Chiaro, M. D., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,356
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Daly, M. B., Pal, T., Berry, M. P., Buys, S. S., Dickson, P., Domchek, S. M., Elkhanany, A. M., Friedman, S., Goggins, M., Hutton, M. L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0001 · Cited by 1,143
Metadata
- Authors
- Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., & Gallinger, S.
- Affiliations
- Mount Sinai Hospital (CA)
- Spring Holter, Ayelet Borgida, Robert Grant, Kara Semotiuk, and Steven Gallinger, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; Anna Dodd, David Hedley, Neesha Dhani, Malcolm Moore, and Steven Gallinger, McCain Pancreatic Cancer Centre, University Health Network; and Steven Narod and Mohammad Akbari, Women's College Research Institute, Toronto, Ontario, Canada.
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2015-10-01
- Volume
- 33
- Issue
- 28
- Pages
- 3124-3129
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2161479848
- Cited by
- 398
- References
- 39
- Citations by year
- 2026: 18 · 2025: 19 · 2024: 23 · 2023: 40 · 2022: 40 · 2021: 71 · 2020: 50 · 2019: 27 · 2018: 42 · 2017: 30 · 2016: 26 · 2015: 12
- FWCI
- 25.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Cancer Society Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- germline BRCA1 mutation, germline BRCA2 mutation, pancreatic ductal adenocarcinoma, family history of cancer, Ashkenazi Jewish ancestry, hereditary cancer predisposition
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA Mutational Analysis, Female, Gene Frequency, Humans, Jews, Male, Middle Aged, Ontario, Pancreatic Neoplasms, Pedigree, Phenotype, Prognosis, Prospective Studies, Risk Factors, Incidence, Germ-Line Mutation, BRCA1 Protein, Genetic Predisposition to Disease, Carcinoma, Pancreatic Ductal, BRCA2 Protein, Heredity, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
